BioXcel Therapeutics Income Statement (2022-2025) | BTAI

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.01M-1.59M0.14M0.24M0.21M0.46M0.34M0.38M0.58M1.10M0.21M0.37M0.17M0.12M0.10M
Gross Profit 0.13M0.23M0.20M0.43M-0.17M-0.34M0.50M1.04M-0.96M-0.47M0.15M0.01M0.09M
Operating items
Amortization - Deferred Charges 0.32M0.22M0.32M0.33M0.36M0.38M0.31M0.04M0.10M0.11M0.22M0.35M0.39M0.44M
Research & Development 18.56M17.91M22.06M32.46M27.80M26.97M19.62M9.93M11.40M8.03M5.10M5.90M4.55M10.26M8.74M
Selling, General & Administrative 12.92M18.38M17.05M20.66M23.59M25.87M24.34M9.60M13.26M9.45M7.68M4.09M5.70M5.61M5.38M
Restructuring Costs 4.16M0.86M1.55M0.03M0.19M
Other Operating Expenses 0.01M0.01M0.01M0.03M0.51M0.71M0.08M0.06M1.17M0.83M0.01M0.11M0.01M
Operating Expenses 31.48M36.29M39.13M53.13M51.40M52.87M48.64M20.25M24.75M18.40M15.51M10.86M10.27M15.97M14.33M
Operating Income -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M
EBIT -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M
Non-operating items
Interest & Investment Income 0.01M0.20M0.82M1.49M2.02M1.62M1.07M0.95M0.95M0.67M0.62M0.37M0.28M0.23M0.24M
Other Non Operating Income 0.06M-0.48M-0.25M0.54M-0.01M0.11M0.03M12.03M4.82M3.30M6.56M0.66M-12.55M
Non Operating Income 0.06M-0.48M-0.25M0.54M-0.01M0.11M0.03M12.03M4.82M3.30M6.56M0.66M-12.55M
Net income details
EBT -31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M
Profit After Tax -31.47M-37.67M-41.80M-54.81M-52.80M-53.52M-50.49M-22.26M-26.79M-8.30M-13.65M-10.86M-7.25M-19.19M-30.91M
Income from Continuing Operations -31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M
Consolidated Net Income -31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M
Income towards Parent Company -31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M
Net Income towards Common Stockholders -31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M
Additional items
EPS (Basic) -1.12-1.35-1.49-1.96-1.84-1.83-1.72-92.93-13.89-3.30-5.15-5.58-1.50-2.45-2.18
EPS (Weighted Average and Diluted) -1.12-1.35-1.49-1.96-1.84-1.83-1.72-92.93-13.89-3.30-5.15-5.58-1.50-2.45-2.18
Shares Outstanding (Weighted Average) 27.98M27.99M28.02M28.02M28.62M29.19M29.27M1.82M1.93M2.52M2.65M2.54M4.83M7.84M14.20M
Shares Outstanding (Diluted Average) 0.03M27.99M28.02M28.02M28.62M29.19M29.27M1.82M1.93M2.52M2.65M2.54M4.83M7.84M14.20M
EBITDA -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M
Interest Expenses 0.01M1.59M3.70M2.92M3.37M3.26M3.25M3.44M3.61M3.70M3.79M4.03M3.99M4.22M4.37M